LTR PHARMA ORD
LTR Pharma Unveils Strong SPONTAN Data and Dual US Strategy
LTR Pharma reports SPONTAN PK: 5 mg intranasal Tmax 10 min vs 60 min oral; FDA 505(b)(2) pathway; dual US strategy; $24.1m cash, 2026 milestones
LTR Pharma Strengthens SPONTAN Market Readiness With Extended Shelf Life
LTR Pharma (ASX: LTP) has extended the shelf life of its SPONTAN intranasal erectile dysfunction (ED) spray to 18 months, a milestone that strengthens its commercialisation prospects in Australia and key international markets. The achievement, confirmed under International Council for Harmonisation stability conditions, demonstrates both chemical and device reliability across the extended period. It positions […]
Weekly wrap: six days of gains as rate cuts outlook improves
Expectations of central bank interest rate cuts drove global markets higher, carrying the Australian market up for its sixth straight day of gains. Stronger than expected US retail spending prompted a solid day on Wall Street after retail sales data topped expectations and jobless applications were lower than expected. That strength carried over on to […]
LTR Pharma partners with Aptar to advance SPONTAN ED nasal spray in key global markets
LTR Pharma (ASX: LTP) and US-based Aptar Pharma have entered into a co-development agreement to commercialise LTR’s SPONTAN erectile dysfunction nasal spray in the US and other key markets. The agreement will combine LTR’s pharmaceutical development capabilities with Aptar’s expertise in nasal spray technology to support a streamlined regulatory pathway and market access for the […]
